Physician profile
Richa Sharma
NPI 1710291562
$1,095.06
in general payments reported to CMS, 2019-2025
14 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.41 · 2020: $63.05 · 2021: $137 · 2022: $311 · 2023: $199 · 2024: $213 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.46 | 2019-2025 | Gardasil 9, Proquad, Gardasil |
| Sanofi Pasteur INC. | $202.73 | 2022-2025 | |
| Corium, LLC | $144.96 | 2022-2024 | Azstarys |
| Glaxosmithkline, LLC. | $138.41 | 2020-2025 | Bexsero, Pediarix |
| Abbvie INC. | $91.84 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $83.17 | 2023-2024 | Jornay Pm |
| Sobi, INC | $65.45 | 2022-2023 | |
| Pfizer INC. | $32.57 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $25.13 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $22.43 | 2023 | Flumist Quadrivalent |
| Novo Nordisk INC | $20.79 | 2023 | Wegovy |
| Amgen INC. | $15.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2021 | |
| Lilly USA, LLC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.